Vertex Pharmaceuticals Incorporated
VRTX
$401.08
$0.920.23%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -6.42% | 13.06% | 30.85% | -14.54% | -11.99% |
| Total Depreciation and Amortization | 12.11% | 1.69% | 6.70% | 1.04% | 4.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,076.19% | 103.08% | -404.02% | -92.82% | 437.30% |
| Change in Net Operating Assets | -544.10% | -23.02% | 76.67% | 252.81% | -212.50% |
| Cash from Operations | -81.50% | 11.81% | 26.06% | -16.55% | 12.86% |
| Capital Expenditure | -43.10% | 31.88% | -41.57% | -25.30% | 38.01% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -974.45% | 68.44% | 86.36% | -956.36% | 713.49% |
| Cash from Investing | -653.19% | 61.27% | 83.43% | -1,144.19% | 145.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.19% | -2.73% | -3.77% | -1.92% | 78.99% |
| Issuance of Common Stock | 201.30% | -73.72% | 312.68% | -72.48% | 40.98% |
| Repurchase of Common Stock | 10.28% | -442.04% | 89.51% | -14,157.14% | 95.63% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -400.00% | 0.00% | 0.00% | 145.83% | -442.86% |
| Cash from Financing | 27.39% | -1,053.76% | 105.87% | -833.08% | 166.78% |
| Foreign Exchange rate Adjustments | 221.78% | -325.00% | -16.67% | -70.59% | 206.81% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -177.27% | 12.29% | 170.52% | -191.12% | 182.30% |
